Resumen
La bivalirudina, análogo sintético de la hirudina que se une reversiblemente a la trombina, pertenece al grupo de anticoagulantes que son inhibidores directos de la trombina con un efecto muy predecible. El objetivo de esta revisión es responder a la pregunta: ¿cuáles son la eficacia y la seguridad del tratamiento con bivalirudina en pacientes con síndrome coronario agudo sin elevación del ST, en comparación con la combinación de heparina (no fraccionada o de bajo peso molecular) e inhibidores de la glucoproteína IIb/IIIa? Ambas estrategias han sido comparadas en dos estudios (ACUITY y REPLACE-2), de diseño e interpretación difícil, y que han mostrado una eficacia en términos de prevención de eventos cardiacos similar y disminución de las complicaciones hemorrágicas en los grupos asignados a recibir tratamiento con bivalirudina. Se realiza un análisis crítico de las evidencias y de las limitaciones existentes, que pueden servir de base para implantar una u otra estrategia en los protocolos de manejo del síndrome coronario agudo sin elevación del ST.
Palabras clave
Síndrome coronario agudo
Angina inestable
Infarto de miocardio
Heparina
Bivalirudina
Inhibidores de la glucoproteína IIb/IIIa
Este artículo solo puede leerse en
pdf
Bibliografía
[1.]
J.L. Anderson, C.D. Adams, E.M. Antman, C.R. Bridges, R.M. Califf, D.E. Casey Jr., et al.
ACC/AHA 2007 guidelines for the management of patients with unstable angina/non-ST-elevation myocardial infarction: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Writing Committee to Revise the 2002 Guidelines for the Management of Patients With Unstable Angina/Non-ST-Elevation Myocardial Infarction).
Circulation, (2007), 116 pp. e148-e304
[2.]
J.P. Bassand, C.W. Hamm, D. Ardissino, E. Boersma, A. Budaj, F. Fernández-Avilés, et al.
(Grupo de Trabajo para el diagnóstico y tratamiento del síndrome coronario agudo sin elevación del segmento ST de la Sociedad Europea de Cardiología). Guía de Práctica Clínica para el diagnóstico y tratamiento del síndrome coronario agudo sin elevación del segmento ST.
Rev Esp Cardiol, (2007), 60 pp. e1-e80
[3.]
National Institute for Clinical Excellence. Unstable Angina and NSTEMI: the early management of unstable angina and non-ST-segment-elevation myocardial infarction; Clinical guideline 94. London: UK: National Institute for Health and Clincial Excellence, 2010.
[4.]
J.I. Weitz, M. Bates.
New anticoagulants.
J Thromb Haemost, (2005), 3 pp. 1843-1853
[5.]
S.M. Bates, J.I. Weitz.
The status of new anticoagulants.
Br J Haematol, (2006), 134 pp. 3-19
[6.]
J. Stangier, K. Rathgen, H. Stähle, D. Gansser, W. Roth.
The pharmacokinetics, pharmacodynamics and tolerability of dabigatran etexilate, a new oral direct thrombin inhibitor, in healthy male subjects.
Br J Clin Pharmacol, (2007), 64 pp. 292-303
[7.]
S.J. Connolly, M.D. Ezekowitz, S. Yusuf, J. Eikelboom, J. Oldgren, A. Parekh, The RE-LY Steering Committee and Investigators, et al.
Dabigatran versus warfarin in patients with atrial fibrillation.
N Engl J Med, (2009), 361 pp. 1139-1151
[8.]
E.W. Davie, J.D. Kulman.
An overview of the structure and function of thrombin.
Semin Thromb Hemost, (2006), 32 pp. 3-15
[9.]
S.R. Coughlin.
Thrombin signalling and protease-activated receptors.
Nature, (2000), 407 pp. 258-264
[10.]
J.M. Maraganore, P. Bourdon, J. Jablonski, K.L. Ramachandran, J.W. Fanton.
Design a characterizacion of hirulogs: a novel class of bivalent peptide inhibitors of thrombin.
Biochemistry, (1990), 29 pp. 7095-7101
[11.]
S.M. Bates, J.I. Weitz.
The mechanism of action of throbim inhibitors.
J Invasive Cardiol, (2000), 12 pp. 27F-32F
[12.]
J.I. Weitz, M. Hudoba, D. Massel, J. Maraganore, J. Hirsh.
Clot-bound thrombin is protected from inhibition by heparin-antithrombin III but is susceptible to inactivation by antithrombin III-independent inhibitors.
J Clin Invest, (1990), 86 pp. 385-391
[13.]
Angiox (Bivalirudin) Summary of Product Characteristics. EMEA (European Medicines Agency), 2004. Disponible en : http://www.ema.europa.eu/docs/es_ES/document_library/EPAR_-_Product_Information/human/000562/WC500025076.pdf.
[14.]
G.W. Stone, B.T. McLaurin, D.A. Cox, M.E. Bertrand, A.M. Lincoff, J.W. Moses, et al.
Bivalirudin for patients with acute coronary syndromes.
N Engl J Med, (2006), 355 pp. 2203-2216
[15.]
G.W. Stone, H.D. White, E.M. Ohman, M.E. Bertrand, A.M. Lincoff, B.T. McLaurin, et al.
Bivalirudin in patients with acute coronary syndromes undergoing percutaneous coronary intervention: a subgroup analysis from the Acute Catheterization and Urgent Intervention Triage strategy (ACUITY) trial.
Lancet, (2007), 369 pp. 907-919
[16.]
A.M. Lincoff, J.A. Bittl, R.A. Harrington, N.S. Kleiman, J.D. Jackman, I.J. Sarembock, et al.
Bivalirudin and provisional glycoprotein IIb/IIIa blockade compared with heparin and planned glycoprotein IIb/IIIa blockade during percutaneous coronary intervention: REPLACE-2 randomized trial.
JAMA, (2003), 289 pp. 853-863
[17.]
V. Rajagopal, A.M. Lincoff, D.J. Cohen, H.S. Gurm, T. Hu, W.J. Desmet, et al.
Outcomes of patients with acute coronary syndromes who are treated with bivalirudin during percutaneous coronary intervention: an analysis from the Randomized Evaluation in PCI Linking Angiomax to Reduced Clinical Events (REPLACE-2) trial.
Am Heart J, (2006), 152 pp. 149-154
[18.]
S.V. Rao, E.M. Ohman.
Anticoagulant therapy for percutaneous coronary intervention.
Circ Cardiovasc Interv, (2010), 3 pp. 80-88
[19.]
J.A. Bittl, J. Strony, J.A. Brinker, W.H. Ahmed, C.R. Meckel, B.R. Chaitman, et al.
Treatment with bivalirudina (Hirulog) as compared with heparin during coronary angioplasty for unstable or postinfarction angina. Hirulog Angioplasty Study Investigators.
N Engl J Med, (1995), 333 pp. 764-769
[20.]
G.W. Stone, M. Bertrand, A. Colombo, G. Dangas, M.E. Farkouh, F. Feit, et al.
Acute Catheterization and Urgent Intervention Triage strategY (ACUITY) trial: study design and rationale.
Am Heart J, (2004), 148 pp. 764-775
[21.]
S. Yusuf, F. Zhao, S.R. Mehta, S. Chrolavicius, G. Tognoni, K.K. Fox, Clopidogrel in Unstable Angina to Prevent Recurrent Events Trial Investigators.
Effects of clopidogrel in addition to aspirin in patients with acute coronary syndromes without ST-segment elevation.
N Engl J Med, (2001), 345 pp. 494-502
[22.]
S.V. Manoukian, F. Feit, R. Mehran, M.D. Voeltz, R. Ebrahimi, M. Hamon, et al.
Impact of major bleeding on 30-day mortality and clinical outcomes in patients with acute coronary syndromes an analysis from the ACUITY.
J Am Coll Cardiol, (2007), 49 pp. 1362-1368
[23.]
S. Yusuf, S.R. Mehta, S. Chrolavicius, R. Afzal, J. Pogue, C.B. Granger, Fifth Organization to Assess Strategies in Acute Ischemic Syndromes Investigators, et al.
Comparison of fondaparinux and enoxaparin in acute coronary syndromes.
N Engl J Med, (2006), 354 pp. 1464-1476
[24.]
G.W. Stone, J.H. Ware, M.E. Bertrand, A.M. Lincoff, J.W. Moses, E.M. Ohman, et al.
Antithrombotic strategies in patients with acute coronary syndromes undergoing early invasive management. One-year results from the ACUITY Trial.
JAMA, (2007), 298 pp. 2497-2506
[25.]
T.A. Sanborn, R. Ebrahimi, S.V. Manoukian, B.T. McLaurin, D.A. Cox, F. Feit, et al.
Impact of femoral vascular closure devices and antithrombotic therapy on access site bleeding in acute coronary syndromes. The Acute Catheterization and Urgent Intervention Triage Strategy (ACUITY) Trial.
Circ Cardiovasc Interv, (2010), 3 pp. 57-62
[26.]
R.D. Lopes, K.P. Alexander, S.V. Manoukian, M.E. Bertrand, F. Feit, H.D. White, et al.
Advanced age, antithrombotic strategy, and bleeding in non-ST-segment elevation acute coronary syndromes: results from the ACUITY (Acute Catheterization and Urgent Intervention Triage Strategy) trial.
J Am Coll Cardiol, (2009), 53 pp. 1021-1030
Copyright ©
2011. Sociedad Española de Cardiología